Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity Therapeutics Limited - American Depositary Shares (ATHE)
Company Research
Source: PR Newswire
MELBOURNE, Austrilia and SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting.Chief Medical Officer & Senior VP Clinical Development, Dr David Stamler had been invited to make an oral presentation at the Parkinson's Disease Interventions and Clinical Trials session at the AAN Annual meeting in Toronto in April 2020 but the meeting was cancelled due to the COVID-19 pandemic. This was replaced with the opportunity to make a virtual presentation which is currently live on the 2020 AAN Science Highlights Virtual Platform available here. The presentation was based on an abstract entitled A Phase 1 Study of PBT434, a Novel Small Molecule Inhibitor of a-Synuclein Aggregation, in Adult and Older Adult Volunteers published in the journal Neurology.In addition, Dr Stamler was in
Show less
Read more
Impact Snapshot
Event Time:
ATHE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHE alerts
High impacting Alterity Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ATHE
News
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024GlobeNewswire
- Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundGlobeNewswire
- Alterity Therapeutics Limited (NASDAQ: ATHE) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $4.00 price target on the stock.MarketBeat
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance